Immunophenotyping by Flow Cytometry CD123 Test
Comprehensive Introduction to CD123 Flow Cytometry Testing
The Immunophenotyping by Flow Cytometry CD123 Test represents a cutting-edge diagnostic approach in modern hematology and oncology. This sophisticated laboratory technique provides critical insights into cellular characteristics that are essential for accurate cancer diagnosis and treatment planning. CD123, also known as interleukin-3 receptor alpha chain, serves as a crucial biomarker for identifying specific malignant cell populations in blood and bone marrow samples.
Flow cytometry immunophenotyping has revolutionized how medical professionals detect and characterize hematological malignancies. By analyzing the presence and density of CD123 on cell surfaces, this test enables precise identification of abnormal cell populations that may indicate the presence of leukemia, lymphoma, or other blood disorders. The technology’s ability to rapidly analyze thousands of cells simultaneously makes it an invaluable tool in modern cancer diagnostics.
What the CD123 Test Measures and Detects
The Immunophenotyping by Flow Cytometry CD123 Test specifically measures the expression of CD123 antigen on the surface of cells in blood or bone marrow samples. This comprehensive analysis detects:
- Presence and percentage of CD123-positive cells in the sample
- Intensity of CD123 expression on cell surfaces
- Co-expression patterns with other cell surface markers
- Abnormal cell populations characteristic of specific malignancies
- Cancer stem cells that may be resistant to conventional treatments
CD123 is particularly significant because it’s frequently overexpressed in certain types of leukemia, including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and some forms of acute myeloid leukemia (AML). The test’s precision allows for early detection of minimal residual disease and monitoring of treatment response.
Who Should Consider CD123 Immunophenotyping Testing
This advanced diagnostic test is recommended for individuals experiencing symptoms or clinical findings suggestive of hematological malignancies, including:
Clinical Indications and Symptoms
- Unexplained fatigue, weakness, or persistent tiredness
- Frequent infections or unusual susceptibility to illness
- Unexplained bruising, bleeding, or petechiae
- Enlarged lymph nodes, spleen, or liver
- Unexplained weight loss or night sweats
- Bone pain or tenderness
- Abnormal complete blood count (CBC) results
- Suspected leukemia or lymphoma based on initial screening
- Monitoring treatment response in known hematological malignancies
Patient Populations
- Patients with suspected acute myeloid leukemia (AML)
- Individuals with possible blastic plasmacytoid dendritic cell neoplasm
- Patients being evaluated for hematopoietic stem cell disorders
- Individuals requiring monitoring of minimal residual disease
- Patients being considered for targeted therapy involving CD123
Significant Benefits of CD123 Flow Cytometry Testing
Choosing the Immunophenotyping by Flow Cytometry CD123 Test provides numerous advantages for patients and healthcare providers:
Diagnostic Precision
- High sensitivity and specificity for detecting malignant cell populations
- Accurate identification of cancer stem cells and treatment-resistant clones
- Comprehensive characterization of abnormal cell immunophenotypes
- Early detection of disease recurrence or progression
Clinical Management Advantages
- Informs targeted treatment selection and personalized therapy approaches
- Enables monitoring of treatment efficacy and disease response
- Provides prognostic information for disease outcome prediction
- Supports decisions regarding stem cell transplantation eligibility
Patient-Centered Benefits
- Rapid turnaround time with same-day results available
- Minimally invasive sample collection procedure
- Comprehensive analysis from experienced flow cytometry specialists
- Clear, actionable results for informed medical decision-making
Understanding Your CD123 Test Results
Interpreting CD123 immunophenotyping results requires specialized medical expertise, but understanding the general principles can help patients better comprehend their diagnosis and treatment options.
Normal Results Interpretation
Normal CD123 expression patterns typically show low to absent CD123 on most mature blood cells. Minimal expression may be present on certain dendritic cell subsets and basophils within expected physiological ranges.
Abnormal Findings and Clinical Significance
- Elevated CD123 Expression: May indicate presence of blastic plasmacytoid dendritic cell neoplasm, certain AML subtypes, or other hematological malignancies
- Abnormal Cell Populations: Detection of distinct CD123-positive cell clusters suggests malignant transformation
- Co-expression Patterns: Specific marker combinations help classify disease subtypes and guide treatment selection
- Quantitative Changes: Increasing or decreasing CD123 expression during treatment can indicate response or resistance
Clinical Implications
Your hematologist or oncologist will interpret the results in the context of your complete clinical picture, including symptoms, physical findings, and other laboratory results. The CD123 test results contribute significantly to:
- Establishing accurate diagnosis and disease classification
- Determining appropriate treatment strategies
- Assessing prognosis and potential treatment outcomes
- Monitoring disease progression and treatment response
- Identifying potential candidates for CD123-targeted therapies
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Immunophenotyping by Flow Cytometry CD123 Test | $126 |
| Current Discount Price | $88 |
Testing Process Details
- Turnaround Time: Sample submission by 9 AM; Same-day results
- Sample Requirements: 3 mL whole blood in EDTA tube AND 3 mL whole blood in Sodium Heparin tube OR 2 mL bone marrow in Sodium Heparin tube
- Shipping Instructions: Immediate shipment at 18-22°C – DO NOT REFRIGERATE OR FREEZE
- Documentation: Complete test request form with time, date, and clinical details
Nationwide Testing Availability
We proudly offer comprehensive CD123 immunophenotyping testing services across the United States. Our state-of-the-art flow cytometry laboratories serve patients in all major metropolitan areas including:
- New York City and surrounding tri-state area
- Los Angeles and Southern California region
- Chicago and Midwest locations
- Houston, Dallas, and Texas facilities
- Phoenix, Arizona and Southwest centers
- Philadelphia, Boston, Washington DC, and East Coast locations
- Miami, Atlanta, and Southeastern sites
- San Francisco, Seattle, and West Coast centers
Our network of certified collection centers ensures convenient access to this essential diagnostic testing regardless of your location within the United States.
Take Action for Your Health Today
Don’t wait to get the answers you need for proper diagnosis and treatment planning. The Immunophenotyping by Flow Cytometry CD123 Test provides critical information that can significantly impact your healthcare journey and treatment outcomes.
Call or WhatsApp us now at +1(267) 388-9828 to schedule your CD123 immunophenotyping test. Our knowledgeable staff will guide you through the scheduling process, answer your questions about the testing procedure, and help coordinate sample collection at a location convenient for you.
Early and accurate diagnosis is essential for effective cancer treatment. Take the first step toward comprehensive hematological evaluation by booking your CD123 flow cytometry test today. Our team of experienced hematologists, oncologists, and flow cytometry specialists is ready to provide you with the highest quality diagnostic services and support throughout your testing experience.
